Shield Therapeutics (LSE:STX) Operating Cash Flow per Share : £-0.04 (TTM As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics Operating Cash Flow per Share?

Shield Therapeutics's operating cash flow per share for the six months ended in Jun. 2023 was £-0.03. Shield Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.04.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -29.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Shield Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

LSE:STX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -29.6 Med: 9.3 Max: 55.9
Current: -29.6

During the past 9 years, Shield Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 55.90% per year. The lowest was -29.60% per year. And the median was 9.30% per year.

LSE:STX's 3-Year OCF Growth Rate is ranked worse than
87.34% of 806 companies
in the Drug Manufacturers industry
Industry Median: 7.45 vs LSE:STX: -29.60

Shield Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Shield Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics Operating Cash Flow per Share Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.03

-0.01

-0.09

-0.07

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Operating Cash Flow per Share	Get a 7-Day Free Trial													-0.04	-0.05	-0.07	-0.01	-0.03

Competitive Comparison of Shield Therapeutics's Operating Cash Flow per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Price-to-Operating-Cash-Flow falls into.

Shield Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Shield Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (A: Dec. 2022 )	=	Cash Flow from Operations (A: Dec. 2022 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2022 )
	=	-17.312	/	233.191
	=	-0.07

Shield Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2022 is calculated as

Operating Cash Flow per Share (Q: Jun. 2023 )	=	Cash Flow from Operations (Q: Jun. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Jun. 2023 )
	=	-19.896	/	702.902
	=	-0.03

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.04

Shield Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.